allergan so long and janssen pharmaceuticals. in putting this lawsuit together. we believe these companies are culpable for the tragic heartbreaking number of oklahomans who have become addicted or who have died as a result of the opioid epidemic in our state. he's the oklahoma attorney general and the 1st one in his country to go to battle. my counter is publicly accusing pharmaceutical companies of having caused this epidemic. he wanted to prove that he and his team have been investigating for more than a year. yes my name is regina whitton an attorney here in oak on the city . in my mind this model burrage my lawyer. general hunter hired my law firm burrage to represent the state of oklahoma and. try to recoup all of the costs that the state has incurred because of the opioid epidemic we need this person and say. yes. i think we're going to be able to prove that 80 percent of all the crime in the state of oklahoma is directly caused by this opioid epidemic and our prisons are overfilled because of that loss of productivity of taxpaying citizens costs the state

so where are you versus the drug allergan had it a power house marketer and i wonder how little bio havenan go up against big avy. >> you can imagine we get that question a lot we're a small company but as i like to say, we're a modern day pharm ak pharma company we use social media and tele medicine and also we're innovative and creative in ways like the take back today campaign so what i can tell you is for the last four months, we've gone toe to toe with our larger former competitor and when we first came into this space, you have to remember they had a two-month lead on us and 100% of the market i can tell you that as of today, we're splitting the market with them so little bio haven has managed to get about half of the market from the larger competitor and we think we're within striking distance becoming the market leader in the new brands or nbrx stats that will be coming out in the coming weeks we think we're about to surpass them in market share. >> one last question i usually don't do this because i don't like to speculate unless the fundamentals are good but your fund mentals ar

partnering with in a significant way was valeant when he partnered with them in their hostile bid for allergan>> didn't he end up doing burger king >> he did, in terms of spacs or in terms of -- yes, absolutely that was a good investment. >> let's be more objective, david, like me >> okay. i'm still waiting for something. >> see, carl, i'm jimmy chill. i immediately point out burger king when he points out valeant. it's not the old days, carl. i'm just not that guy. >> you've been pretty resolute in your chill, jim it's been months now. >> it is not easy. i have people -- i mean, cramer and portnoy, i've been saying -- i haven't blocked portnoy. portnoy, he had -- what, he was up 10,000 yesterday, he was up 30, i think. you check that every day, right, david? >> there something going on where you have to mention portnoy's name four or five times in the first ten minutes of our show. >> we're about to get sports and i want to know is he going away. more advice on baseball or betting on someone than we do on whether he likes the four letters that come out of a bag hello? >> if he goes away do a

she didn't know about it a long time ago i'm trying to get people to know about the cprg drugs allergannow too >> see you tonight >> harley. >> see you later >> welcome to "squawk on the street." i'm carl quintanilla with david faber and leslie picker this morning. interesting market day again the vaccine hopes plus goldman and good macro data, as the dow inches up. to a large degree, it is largely about moderna, astrazeneca and the hopes for a vaccine down the road >> that seems to be reflected in the broader market averages being up almost 1% and the s&p basically flat for the year. moderna is up sharply on the promising results from the study of the experimental vaccine. meg is here with the latest. >> this is the full phase one study of moderna's covid-19 vaccine. in may we got a glimpse at the data it's only 8 of the 45 p participants worth of the information. here we have the full data set it looked at 45 healthy participants between the ages of 18 and 55 and got two doses of the vaccine 28 days apart. they found every one of the volunteers generated neutralizing antibodies. the a